No significant difference existed in TMB between FGFR1 SV-altered versus SV-unaltered gliomas [TMB-high: 5/239, 2.1%, versus 460/11 311, 4.1%; odds ratio = 1.98; P = 0.14; median TMB 1.25 (IQR 0.87-2.61) versus 1.74 (IQR 0.87-3.48); Supplementary Figure S6, available at https://doi.org/10.1016/j.esmoop.2022.100641]. This evidence concerns the gene FGFR1 and central nervous system cancer.